Beckman Coulter, Inc.
 

Products

   
   
 
 

  ArrayPlex -- Application for Microarray Target Preparation

Printer Friendly


Related Product Information

 
Providing GeneChip* customers a reliable sample preparation workstation for large-scale gene expression studies

Beckman Coulter's ArrayPlex application has earned Affymetrix Premier Application Status. This provides to GeneChip customers a reliable sample preparation work-station for large-scale gene expression studies that meets Affymetrix' validation specifications.


Product Features
Hgher Throughput

Automated target RNA sample processing in 36 hours -- six times that of a single technician holding an manual pipettor.

  • Eliminate pipetting errors
  • Improve consistency

Scalability

  • Process experimental and control samples in batches of eight, up to 96 in a full microplate
  • Application available on smaller-footprint Biomek® 3000

Versatility

  • Automated methods to provide for all your nucleic acid preparation and cleanup needs are available from Beckman Coulter

Flexibility

  • Filtration or magnetic bead cleanup steps
  • Compatible with both Affymetrix and Enzo IVT labeling reagents

Reliability

  • Fully validated robust solution
  • Increased performance of GeneChip hybridization
  • ArrayPlex is distributed and supported by Beckman Coulter, assuring world-class service and support

More Info
Click to enlarge image
Work-Flow For Target RNA Prep on the ArrayPlex

Work-Flow For Target RNA Prep on the ArrayPlex


Affymetrix Preferred Application Provider Status

To satisfy Affymetrix acceptance criteria, two operators on different instrument platforms were required to process 1 and 2 µg aliquots of total RNA islated from HeLa cells. A total of 240 samples were processed using Affymetrix brand cDNA and IVT reagents. Reaction cleanup was done by filtration using Qiagen MinElute* and RNeasy cleanup kits. The quality of the cRNA product was determined by hybridization of a random sample to 60 Human U133 plus 2 Gene Chips. A summary of the data is shown below.

Click to enlarge image

BioAnalyzer Electropherogram: cRNA size distribution generated during automated processing of 1 µg and 2 µg total RNA samples

Click to enlarge image

Affymetrix Human U133 plus 2.0 GeneChip cartridge scan of HeLa total RNA

Click to enlarge image

Log correlation analysis between replicates of HeLa samples at 1 µg target level generated using GCOS 1.2. Green parallel lines indicate two-fold change

Parameter Acceptance Criteria Observed
(% CV)
Pass/Fail
Yield (1 µg target) > 25 µg 32 µg Pass
Yield (2 µg target) > 25 µg 52 µg Pass
% Present > 53 (< 5%) 55.3 (2.3%) Pass
β-Actin 3'/5' ratio (< 10%) 1.5 (8.2%) Pass
GAPDH 3'/5' ratio (< 10%) 0.99 (2.7%) Pass
% False Change 0.75 0.28 Pass
Pearson Correlation 0.94 - 0.96 0.94 Pass
Summary table of results from 60 GeneChips analyzed. The ArrayPlex generated the quantity and quality of target RNA necessary to meet the acceptance criteria for each of the parameters set by Affymetrix.


ArrayPlex Enables Newly Trained NIDDK Technician to Score at the Top of the 18-lab Peer Proficiency Study

National Institutes of Health (NIH) Instrument Qualification Study

For the NIH qualification study, target prep was done by a newly trained NIDDK (National Institute of Diabetes and Digestive and Kidney Diseases) technician on the ArraPlex using two sets of six rat total RNA samples (isolated from the tissue pools). A total of 12 samples were processed using Affymetrix cDNA and ENZO IVT reagents. Reaction cleanup was done by filtration using Qiagen MinElute and RNeasy cleanup kits. The quality of the cRNA product was monitored by an outside evaluator, Expression Analysis, Inc., who determined the lab performed at the top of the 18-lab peer profeciency study (see below).

Click to enlarge image

BioAnalyzer Electropherogram: cRNA size distribution generated from 2 µg total RNA rat tissue pools

Click to enlarge image

Graphical representation of how the NIDDK lab performed in comparison to the 18-lab peer proficiency study reviewed by Expression Analysis, Inc.

Measurement
(Lab Average)
Sample Set #1 Sample Set #2 Peer Average
Noise 2.00 2.01 2.40
GAPDH 3'/5' ratio 1.04 1.09 1.45
β-Actin 3'/5' ratio 2.02 2.07 2.94
% Present 65.4 64.6 59.5
Signal Present 992 1016 1057
False Positives 1.24% 1.48% 2.56%
Summary table of results from two sets of 6 GeneChips analyzed using target RNA generated on the ArrayPlex


ArrayPlex Validation Study

The ArrayPlex validation study was initiated to identify sources of variation in target RNA prep by comparison of one operator on the ArrayPlex vs. two skilled laboratory techinicians performing the process manually. The commercially available Human Reference RNA product from Stratagene (San Diego, CA) was used as the source of total RNA. The samples were processed using Invitrogen cDNA and ENZO IVT reagents, both manually and on the automation platform. A total of 12 samples from each picked for comparison by hybridization to 24 Human U133 Plus 2 GeneChips. The results are shown below.

  Automated Manual
Measurement
(Average)
Plate 8 wells Plate 96 wells Techinician 1 Techinician 2
Background 44.2 54.5 43.9 44.7
GAPDH 3'/5' ratio 0.89 0.87 0.88 0.88
β-Actin 3'/5' ratio 1.01 0.99 1.21 1.13
% Present        
  2 g 57.8 57.1 56.4 56.4
  5 g 56.8 56.2 52 56.4
  7.5 g 57.7 56.3 52.9 55.7
Signal Present 790 791 802 800

Summary table of averaged results from each set of 6 GeneChips analyzed using target RNA generated from either automated or manual processing methods. Variation in target RNA prep is revealed in the ANOVA (right).

ANOVA of Affymetrix Human U133 Plus 2 GeneChip Percent Present

Click to enlarge image
Biomek 3000

* All trademarks are the property of their respective owners.

For Research Use Only; not for use in diagnostic procedures.

Ordering Information

For ordering information, please contact your local Beckman Coulter representative.

Additional Information:


 

 
 
Home | Products | Customer Support | Resource Center
Employment | Our Company | Contact Us | Site Map
 Privacy©1998 - 2008 Beckman Coulter, Inc.